Giuseppe Caruso, Gynecologic Oncologist Consultant at IEO European Institute of Oncology IRCCS (Milan, Italy), shared a post on LinkedIn:
“Very happy to see ADCs finally moving earlier in cervical cancer – because in real life, using them late is often too late!
Recurrent/metastatic cervical cancer is still an unmet need. In daily practice, when we give Tisotumab Vedotin (TV) after immunotherapy, patients are often already compromised – fistulas, nephrostomies, frailty. That’s not when you unlock the full potential of an ADC.
The 5-year innovaTV 205 data clearly show that TV-based combinations (triplet/quadruplet regimens) are active and durable, especially in 1L, with response rates up to ~66% and OS approaching 2+ years.
If we believe in these drugs, we should use them earlier – not as a last resort.
This shift toward early lines is not just interesting. It’s necessary.
Looking forward to seeing results of ongoing phase III trials, such as TroFuse-036, in this setting.”
Title: Tisotumab vedotin plus carboplatin or pembrolizumab in recurrent or metastatic cervical cancer: 5-year results from the innovaTV 205/ENGOT-cx8/GOG-3024 study
Authors: Els Van Nieuwenhuysen, Ignace Vergote, Leslie Randall, Jacqueline Tromp, Domenica Lorusso, Roisin O’Cearbhaill, Ingrid Boere, Carmela Pisano, Luis Manso Sanchez, Susana Banerjee, Dearbhaile Collins, Michal Zikán, Cara Mathews, Jan Kümmel, Bohuslav Melichar, Amanda Jackson, Kristine Madsen, Christine Gennigens, Nelleke Ottevanger, Sharad Ghamande, Bradley Monk
Other articles featuring Giuseppe Caruso on OncoDaily.